Melanoma

A Curated Room: The People Shaping Practice

Now in its second year, this invitation-only meeting convenes a deliberately small faculty: 24 leading melanoma KOLs alongside 29 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.

The program follows melanoma from stage II and III risk assessment and adjuvant and neoadjuvant therapy, through stage IV immunotherapy, multidisciplinary management and cellular therapy, to uveal, mucosal and pediatric disease and survivorship. Every session pairs expert talks with a moderated panel, sustained, close-quarters engagement rather than a lecture hall.